
The discovery of yet another COVID variant could be a boon to pharmaceutical companies which have already cashed in on vaccines and are moving with lightning fast speed to produce yet another “jab” to protect against the omicron strain, the latest in a potentially endless string of mutations that could fuel the industry for years to come.










In November, we carried an article by globalresearch that said the Italian Higher Institute of Health had drastically reduced the country’s official COVID death toll number by over 97 per cent after changing the definition of a fatality to someone who died from COVID rather than with COVID.



